Viewray (VRAY) Downgraded by BidaskClub

Viewray (NASDAQ:VRAY) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Thursday.

Several other research firms also recently commented on VRAY. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Viewray in a report on Friday, May 11th. ValuEngine raised shares of Viewray from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. B. Riley started coverage on shares of Viewray in a report on Thursday, February 8th. They issued a “buy” rating and a $13.50 price objective for the company. Finally, Mizuho reissued a “buy” rating and issued a $12.00 price target on shares of Viewray in a report on Thursday, April 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $11.58.

Viewray opened at $6.90 on Thursday, according to Marketbeat.com. The company has a market capitalization of $495.75 million, a P/E ratio of -6.63 and a beta of 0.59. Viewray has a 12 month low of $6.74 and a 12 month high of $7.02. The company has a quick ratio of 3.04, a current ratio of 3.79 and a debt-to-equity ratio of 0.77.

Viewray (NASDAQ:VRAY) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.09. The company had revenue of $26.19 million during the quarter, compared to the consensus estimate of $15.50 million. Viewray had a negative net margin of 83.09% and a negative return on equity of 1,375.57%. Viewray’s revenue for the quarter was up 2029.3% on a year-over-year basis. During the same period last year, the firm earned ($0.54) EPS. equities analysts expect that Viewray will post -0.67 earnings per share for the current year.

In other Viewray news, insider James F. Dempsey sold 75,243 shares of the firm’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $7.57, for a total value of $569,589.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 62.81% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in VRAY. Fosun International Ltd boosted its holdings in Viewray by 61.2% in the 1st quarter. Fosun International Ltd now owns 10,767,975 shares of the company’s stock valued at $69,239,000 after purchasing an additional 4,090,000 shares during the period. Park West Asset Management LLC bought a new position in Viewray in the 4th quarter valued at $24,217,000. Sectoral Asset Management Inc bought a new position in Viewray in the 4th quarter valued at $8,772,000. Citadel Advisors LLC boosted its holdings in Viewray by 2,115.4% in the 4th quarter. Citadel Advisors LLC now owns 669,054 shares of the company’s stock valued at $6,195,000 after purchasing an additional 638,854 shares during the period. Finally, EAM Investors LLC bought a new position in Viewray in the 4th quarter valued at $4,463,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply